|Bid||0.5712 x 2400|
|Ask||0.5800 x 400|
|Day's Range||0.5600 - 0.6210|
|52 Week Range||0.5600 - 2.1600|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||2.50|
VANCOUVER, Dec. 6, 2017 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) today reported its Neovasc Reducer™ ("Reducer") medical device was featured in a "live case" broadcast at the 2017 Innovations in Cardiovascular Interventions (ICI) conference held in Tel Aviv, Israel. In the live case broadcast to the conference from the Soroka University Medical Center in Beersheba Israel, Drs. Koifman and Bazan successfully implanted a Reducer in the coronary sinus of a patient suffering from very poor quality of life due to refractory angina pectoris, chest discomfort felt with even minimal effort, despite previous bypass surgery and multiple stent implantations. The live Reducer case was broadcast following a scientific presentation describing current available clinical data supporting the use of the Reducer as a safe and effective therapy for patients with refractory angina pectoris.
Categories: Yahoo FinanceGet free summary analysis Neovasc, Inc. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of Neovasc, Inc. – Integra LifeSciences Holdings Corporation and ICU Medical, Inc. (IART-US and ICUI-US) that have also reported for this period. Highlights Summary numbers: Revenues of USD 1.37 million, ... Read more (Read more...)
VANCOUVER, Nov. 27, 2017 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NVCN) (NVC.TO) today announced that Chris Clark, chief financial officer, is scheduled to present at the 29th Annual Piper Jaffray Healthcare Conference on Wednesday, November 29th at 7:50 am ET at the Lotte New York Palace in New York City. A live audio webcast of the presentation will be available on the Investors page of Neovasc's website at www.neovasc.com. Neovasc is a specialty medical device company that develops, manufactures and markets products for the rapidly growing cardiovascular marketplace. Its products include the Neovasc Reducer™, for the treatment of refractory angina which is not currently available in the United States and has been available in Europe since 2015 and the Tiara™, for the transcatheter treatment of mitral valve disease, which is currently under investigation in the United States, Canada and Europe.
Neovasc Closes Offering of Units Consisting of Common Shares and Warrants and Concurrent Private Placement of Notes and Warrants
VANCOUVER, Nov. 17, 2017 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) is pleased to announce the closing of its previously announced underwritten offering of 6,609,588 Series A units (the "Series A Units") and 19,066,780 Series B units (the "Series B Units" and together with the Series A Units, the "Units") of the Company, at a price of US$1.46 per Unit for gross proceeds of approximately US$37,487,497, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by Neovasc (the "Offering"). Concurrent with the Offering, the Company completed a private placement for the sale of US$32,750,000 aggregate principal amount of senior secured convertible notes and Series E warrants of the Company for gross proceeds of US$27,837,500 (the "Concurrent Private Placement").
Neovasc Inc (TSX:NVCN), a healthcare equipment and supplies company based in Canada, saw significant share price volatility over the past couple of months on the TSX, rising to the highsRead More...
On a per-share basis, the Richmond, British Columbia-based company said it had a loss of 6 cents. The medical device company posted revenue of $1.4 million in the period. The company's shares closed at ...
NASDAQ, TSX: NVCN VANCOUVER , Nov. 14, 2017 /PRNewswire/ - Neovasc Inc. (" Neovasc " or the " Company ") (NASDAQ, TSX: NVCN) today announced financial results for the third quarter ...
NASDAQ, TSX: NVCN VANCOUVER , Nov. 10, 2017 /PRNewswire/ - Neovasc Inc. (" Neovasc " or the " Company ") (NASDAQ, TSX: NVCN) today announced that it will release its financial results ...
NASDAQ, TSX: NVCN VANCOUVER , Nov. 9, 2017 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (Nasdaq: NVCN) today announced that it has priced an underwritten offering of 6,609,588 ...
Neovasc Announces US$65 Million Underwritten Offering of Units Consisting of Common Shares and Warrants To Purchase Common Shares and Concurrent Private Placement of Notes and Warrants
VANCOUVER, Nov. 6, 2017 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) announced that it has received approval of the U.S. Food and Drug Administration ("FDA") to initiate the COSIRA-II IDE pivotal clinical trial. The trial's purpose will be to demonstrate the safety and effectiveness of the Company's novel Reducer system for treatment of patients with refractory angina. Once completed, the trial data is intended to support an application to the FDA for approval to begin marketing Reducer in the United States. "Since its commercial launch in Europe two years ago, Reducer has consistently provided relief of severe symptoms in patients suffering from refractory angina, resulting in significant improvements in their quality of life," commented Neovasc CEO, Alexei Marko.
Neovasc Inc (TSX:NVCN) continues its loss-making streak, announcing a -$5.11M earnings for its latest financial year ending. Cash is crucial to run a business, and if a company burns throughRead More...
If you are looking to invest in Neovasc Inc’s (TSX:NVCN), or currently own the stock, then you need to understand its beta in order to understand how it can affectRead More...
VANCOUVER, Sept. 12, 2017 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) today provided an update on the study progress and clinical performance of the TiaraTM valve, a self-expanding mitral bioprosthesis for transcatheter implantation in patients with Mitral Regurgitation ("MR"), one of the most prevalent valvular heart diseases in western countries. MR is often severe and can lead to heart failure and death.
VANCOUVER, Sept. 5, 2017 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) today announced the European Heart Journal published a clinical review of its Neovasc Reducer™ ("Reducer") device for the treatment of refractory/persistent angina pectoris, a common and disabling medical condition, and a major public health problem that affects millions of patients worldwide. The European Heart Journal is the official general cardiology journal of the European Society of Cardiology. Refractory angina is a common and disabling clinical condition, and a major public health problem, which affects patients' quality of life, and has a significant impact upon health care resources. Persistent angina is common not only in patients who are not good candidates for revascularization, but also in patients following successful revascularization.